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Abstract Genome-wide association studies have identi-
fied SNPs reproducibly associated with type 2 diabetes
(T2D). We examined the effect of genetic predisposition to
T2D on insulin sensitivity and secretion using detailed
phenotyping in overweight individuals with no diagnosis of
T2D. Furthermore, we investigated whether this genetic
predisposition modifies the responses in beta-cell function
and insulin sensitivity to a 24-week dietary intervention.
We genotyped 25 T2D-associated SNPs in 377 white
participants from the RISCK study. Participants underwent
an IVGTT prior to and following a dietary intervention that
aimed to lower saturated fat intake by replacement with
monounsaturated fat or carbohydrate. We composed a
genetic predisposition score (T2D-GPS) by summing the
T2D risk-increasing alleles of the 25 SNPs and tested for
association with insulin secretion and sensitivity at
baseline, and with the change in response to the dietary
intervention. At baseline, a higher T2D-GPS was associ-
ated with lower acute insulin secretion (AIRg 4% lower/
risk allele, P = 0.006) and lower insulin secretion for a
given level of insulin sensitivity, assessed by the disposi-
tion index (DI 5% lower/risk allele, P = 0.002), but not
with insulin sensitivity (Si). T2D-GPS did not modify
changes in insulin secretion, insulin sensitivity or the dis-
position index in response to the dietary interventions to
lower saturated fat. Participants genetically predisposed to
T2D have an impaired ability to compensate for peripheral
insulin resistance with insulin secretion at baseline, but this
does not modify the response to a reduction in dietary
saturated fat through iso-energetic replacement with car-
bohydrate or monounsaturated fat.
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Introduction
Type 2 diabetes (T2D) results from a combination of
insulin resistance and impaired ability of the pancreatic
beta-cell to secrete sufficient insulin (Kahn 2003). Diet
composition, especially the amount and type of dietary fat,
is a recognised environmental risk factor for T2D, which
particularly affects peripheral insulin sensitivity (Parillo
and Riccardi 2004). The quality of dietary carbohydrate is
also important with a higher glycaemic index (GI) diet
being associated with an increased risk of T2D (Barclay
et al. 2008). Genome-wide association studies (GWAS)
have identified loci that show robust association with
increased risk of developing T2D (Saxena et al. 2007;
Sladek et al. 2007; Voight et al. 2010; Zeggini et al. 2007)
and with glycaemic traits (Dupuis et al. 2009). Most of
these SNPs reside in or near genes that have a presumed
role in pancreatic beta-cell dysfunction (Billings and Florez
2010). These loci have mostly been identified using overt
measures of impaired glucose tolerance or frank diabetes;
however, the impact on insulin sensitivity and beta-cell
function has only been assessed using proxy measures.
More detailed phenotyping has the advantage of identify-
ing early-stage defects that exist before impaired fasting
glucose becomes apparent.
In this study, we examined the effect of a T2D genetic
predisposition score (GPS) on beta-cell function and
peripheral insulin sensitivity, assessed by intravenous
glucose tolerance test (IVGTT) in a cohort of overweight
non-diabetic participants at increased cardiometabolic risk
(Jebb et al. 2010). This was in order to determine the effect
of SNPs that have been most robustly associated with T2D
in GWAS on early-stage defects that can precede T2D.
Furthermore, we examined whether this genetic predispo-
sition to T2D influenced changes in insulin sensitivity and
beta-cell function in response to changes in dietary fat and
carbohydrate intake. This was tested in participants in a
24-week dietary intervention study to lower saturated fat
intake through iso-energetic replacement with low or high
GI carbohydrate or monounsaturated fat (MUFA). The
objective of this analysis was to assess whether the T2D-
GPS can act to modify dietary associated changes in
peripheral insulin sensitivity and beta-cell function.
Methods
Original RISCK trial study design
The RISCK trial (ISRCTN29111298) has been described
in detail previously (Jebb et al. 2010). Briefly, men
and women aged 30–70 years (n = 720) at increased
cardiometabolic risk (according to a study-specific scoring
system) but with no diagnosis of T2D were recruited from
the general population (Jebb et al. 2010). All participants
underwent a 4-week run-in period on the ‘reference’ diet
(REF), designed to reflect the high saturated fat intake of a
‘Western diet’. Participants were then randomised to the
REF diet, or one of four diets designed to achieve a target
reduction in saturated fat intake from *18% of energy
(REF diet) to *10% of energy, for 24 weeks; the actual
mean reduction achieved was 7–8% (Jebb et al. 2010). The
REF and intervention diets described in detail previously
(Moore et al. 2009) were designed to be iso-energetic, but
varied in the amount and type of fat and carbohydrate as
follows: high saturated fat and high GI (REF); high MUFA/
high GI; high MUFA/low GI; low fat/high GI; and low fat/
low GI diets. Measurements taken after the run-in REF diet
are referred to in this study as ‘baseline’ measurements. At
baseline, and following the dietary intervention, a fasting
blood sample was collected, anthropometry measured, and
an IVGTT performed.
Ethical approval for the RISCK study was granted from
the National Research Ethics Service and written informed
consent including subsequent genetic analyses was
obtained from participants.
Study cohort
Of the 720 participants, 549 completed the study, and DNA
was available for 512 participants. To reduce heterogeneity
in genetic background, 412 individuals of white European
ancestry, based on self-reported ethnicity, were included in
the analysis. All other ethnic sub-groups were excluded
from these analyses due to their limited size. Following
genotyping quality control procedures (see below), 405
participants were available for analysis at baseline, and 376
completed the dietary intervention. Data from the IVGTT
was available for 377 participants at baseline and for 354 of
those who completed the study.
Of these participants, 48% had fasting glucose
[5.6 mM (impaired fasting glucose), and no participants
had fasting glucose [7 mM (T2D). The characteristics of
the participants included in these analyses are presented in
Table 1.
IVGTT
A short IVGTT protocol was used and described in more
detail elsewhere (Jebb et al. 2010). The area under the plasma
insulin curve up to 19 min was computed to indicate the
degree of endogenous insulin secretion in response to the
glucose challenge (AIRg). Insulin sensitivity (Si) was esti-
mated using the MINMOD Millennium programme (Ver-
sion 6.02). The disposition index (DI) was calculated as the
product of Si and AIRg and is a measure of the beta-cell’s
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ability to compensate for changes in Si (Bergman et al.
2002).
SNP selection and genotyping
Twenty-eight SNPs were identified from GWAS to be
associated with T2D risk (Dupuis et al. 2009; Saxena et al.
2007; Sladek et al. 2007; Voight et al. 2010; Zeggini et al.
2007). SNPs were only selected from GWAS with at least
1,000 individuals in the discovery stage, which after fol-
low-up reached the threshold of genome-wide significance
of P \ 5 9 10-8. Where multiple SNPs resided in or near
the same gene, only SNPs in low linkage disequilibrium
(LD r2 \ 0.3) were selected.
Genotyping was performed by KBiosciences (Hoddes-
don, Herts, UK) using a fluorescence-based competitive
allele-specific PCR (KASPar) technology, and all SNPs had
a call rate [95%. Individuals were excluded if genotyping
was unsuccessful in [10% of SNPs (n = 7). Genotype
distributions of all SNPs were tested for deviation from the
Hardy–Weinberg Equilibrium using the log-likelihood ratio
Chi-square test (1 df) for association. Using a cut-off of
P \ 0.001 excluded three SNPs (rs1470579-IGFBP2;
rs13266634-SLC30A8; rs8042680-VPS33B) from analyses
due to deviation. The remaining 25 SNPs in or near 24
genes were included in the current analyses (Table 2).
Genetic predisposition score
We defined the risk allele of a SNP as the allele associated
with increased risk of developing T2D or with raised fasting
plasma glucose concentration in previous GWAS (Dupuis
et al. 2009; Saxena et al. 2007; Sladek et al. 2007; Voight
et al. 2010; Zeggini et al. 2007). An individual’s genotype
was coded as 0, 1 or 2 depending on the number of the risk
alleles an individual carried for that particular SNP. For
each individual, a GPS was calculated by adding the
number of risk alleles of the 25 SNPs (Table 2). As there is
currently no evidence for interaction between SNPs, a
simple addition of the associated risk alleles for each trait
has been commonly adopted (Hamrefors et al. 2010; Li
et al. 2010; Talmud et al. 2009). For participants with
missing genotypes (\10%), the average count of risk alleles
for the respective SNP was substituted for the missing
genotype for the purpose of calculating the GPS. The GPS
was normally distributed. The SNPs selected for analysis
are presented in Table 2 showing the risk-allele frequency.
Statistical analysis
Distributions of traits were tested for normality; and because
of right skewness Si, AIRg and DI were natural log-trans-
formed for analyses and presented in figures as the geometric
mean and 95% confidence intervals. For interpretation of the
effect of T2D-GPS on traits, the coefficient of association
from the linear regression analysis of log(n)-transformed
traits equated to the percentage change per risk allele.
Due to insufficient power to examine associations of
individual SNPs, we focussed our study on the GPS, which
provides more power. Linear regression analysis was used
to test for associations between GPS (a continuous variable
according to the number of risk alleles) and traits at
baseline, assuming an additive effect of each additional
risk allele, while adjusting for age, gender, centre and BMI.
We additionally tested for curvature in the model by
inclusion of GPS-squared term in the model.
Next, we tested for the effect of GPS to modify the
change in Si, AIRg and DI following 24 weeks of dietary
intervention by an interaction between T2D-GPS and die-
tary intervention group. This was used in a linear regres-
sion model of the association between the GPS and change
in Si, AIRg and DI following intervention, adjusted for
baseline values, age, gender, centre, baseline BMI, diet and
change in weight. The four intervention diets were com-
pared to the REF diet group.
Associations between the individual SNPs and traits at
baseline, and the interaction effects of SNPs and dietary
intervention group on change in trait in response to the
dietary intervention, were tested with linear regression in
the same way GPS were tested, adjusting for the same
covariates. This exploratory analysis was conducted
despite the assumption that we would have low power to
detect small effects of individual SNPs to illustrate the
contribution to the effects of GPS.
Statistical analysis was conducted using Stata 11
(StataCorp, TX, USA). A Bonferroni correction was applied
to the six tests between T2D-GPS and the three traits at
baseline, and to change in response to the intervention
(P = 0.008). We did not correct the associations of indi-
vidual SNPs as we decided to only report the summary
Table 1 Characteristics of participants who were analysed at base-
line and at the end of the study
Participants analysed
at baseline1
Participants who
completed study2
n 377 354
Age 53.2 (9.9) 53.5 (10)
Female (%) 58 57
BMI 28.8 (4.6) 28.7 (4.5)
Fasting glucose 5.5 (0.6) 5.5 (0.6)
Fasting plasma
glucose [5.6 (%)
48 49
Characteristics of participants at entry into the study, who were
included in the analysis of association of T2D-GPS with (1) traits at
baseline and (2) the change in traits following the dietary interven-
tion. Data are presented as mean (SD) or per cent
Genes Nutr (2012) 7:529–536 531
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statistics for future research, rather than to interpret them on
their own due to the limited statistical power to detect small
individual effects when corrected for false positive chance.
Results
At baseline, we observed no association of T2D-GPS with
peripheral insulin sensitivity (Si) (Fig. 1a). However, the
T2D-GPS was associated with lower acute insulin secretion
(4% per risk allele, P = 0.006, Fig. 1b) and with a lower
disposition index (5% per risk allele, P = 0.002, Fig. 1c).
Of all the SNPs tested, only the TCF7L2 SNP rs7901695
(Table 2) showed a convincing association with both AIRg
(13% lower per risk allele, P = 0.00005) and DI (11%
lower per risk allele, P = 0.001), but not with Si. To
examine whether the associations observed for the GPS
with AIRg and DI were driven by the effect of the TCF7L2
Fig. 1 Effect of type 2 diabetes
genetic predisposition score
(T2D-GPS) on insulin
sensitivity (Si), acute insulin
secretion (AIRg) and
disposition index (DI) at
baseline. The participants were
stratified by T2D-GPS, and the
number of participants in each
GPS stratum is shown in panel
d. The effect of T2D-GPS on
(a) Insulin sensitivity index (Si)
(b) Acute insulin secretion
(AIRg) and (c) Disposition
index (DI) is presented as
geometric mean and 95% CI.
Data were log(n)-transformed
for analysis, and the per allele
effect was determined by linear
regression analysis with age,
gender, BMI and centre as
confounding variables. The
effect is presented as the beta-
coefficient from the linear
regression of the log(n)-
transformed trait (which
equated to percentage
difference) and the P value.
These measures were conducted
after a 1-month period on a
‘reference’ high SFA diet prior
to the dietary intervention to
lower SFA intake
Genes Nutr (2012) 7:529–536 533
123
SNP, we excluded this SNP from the GPS and tested for
association again. The associations remained for AIRg (3%
lower per risk allele, P \ 0.05) and DI (4% lower per risk
allele, P = 0.02), but the effect was diminished, and they
were no longer significant when accounting for multiple
testing.
In response to the 24 week dietary interventions to
lower saturated fat intake, there were no effects of T2D-
GPS to modify the change in Si, AIRg or DI, accounting
for baseline values, in response to any of the dietary
interventions (Table 3).
Of all the SNPs tested, no convincing effect was
observed on the change in Si, AIRg or DI in response to
any of the dietary interventions (Supplementary Table 1).
Discussion
This study used detailed phenotyping from the IVGTT to
characterise the effects of genetic predisposition to T2D on
insulin secretion and sensitivity in non-diabetic overweight
participants at increased cardiometabolic risk. Our results
show that at baseline, a genetic predisposition to T2D was
associated with an impairment of beta-cell function, but
not with insulin sensitivity in participants on a run-in diet
high in saturated fat, designed to reflect a ‘Western diet’.
However, genetic predisposition to T2D did not modify
changes in insulin sensitivity or beta-cell function in
response to a dietary intervention to lower saturated fat
intake by isoenergetic replacement with MUFA or
carbohydrate.
Previous GWAS have identified genetic loci associated
with T2D, the majority of which have a presumed role in
beta-cell dysfunction (Billings and Florez 2010). Our
findings are supportive of a mechanism contributing to
impaired insulin secretion but not insulin sensitivity. The
DI is a more informative measure of beta-cell function than
acute insulin secretion; by taking into account the insulin
sensitivity it is a measure of the ability of the beta-cell to
compensate for the degree of insulin sensitivity (Bergman
et al. 2002). This measure can also be more sensitive as
differences in DI can be detected before changes in acute
insulin secretion are apparent (Bergman et al. 2002). At
baseline, genetic predisposition to T2D was associated
with a lower acute insulin response, but also with a lower
DI, which confirmed an impaired acute insulin response for
the level of insulin resistance.
The dietary modifications in the RISCK study were
designed to be achievable through simple dietary modifi-
cation and implementable on a population scale, but pro-
duced no overall significant effect on insulin sensitivity
(Jebb et al. 2010). Here we demonstrate that genetic pre-
disposition to T2D did not moderate any effects of the T
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dietary intervention on changes in insulin secretion or
sensitivity. An effect of genetic predisposition on changes
in these measures may have been evident with a more
extreme intervention, particularly one that also achieved
weight loss. For example, in response to a lifestyle inter-
vention to decrease caloric intake and increase energy
expenditure (TULIP, n = 1576), carriers of the rs7903146
(TCF7L2) risk allele, who had impaired glucose tolerance
prior to the intervention, showed an increase in post-glu-
cose-load insulin secretion (adjusted for change in BMI),
which was not shown in non-carriers (Heni et al. 2010).
The same locus had also previously been associated with
increased risk of progression to T2D, which was lessened
by metformin therapy in the diabetes prevention pro-
gramme (DPP), a larger multi-ethnic cohort at high risk of
developing T2D (n = 3548) (Florez et al. 2006). Several
other SNPs were also identified to have nominal interac-
tions with metformin on incidence of T2D (n = 2994)
(Jablonski et al. 2010) or in treatment response (n = 3920)
(Zhou et al. 2011). However, also in participants of the
DPP (n = 2843), insulin sensitivity indices were studied
using a genetic risk score (analogous to our GPS and with
23 of 34 SNPs covered in our study). Similar to the current
study, they found a trend for a lower estimated insulin
secretion (insulinogenic index) and oral DI (from a 2 h
post-oral glucose load value) at baseline, but there was also
no overt effect of GPS on change in insulin sensitivity or
secretion indices following 1 year of intensive lifestyle
modification or metformin treatment (Hivert et al. 2011). It
appears that SNPs that are more strongly associated with a
given trait in cross-sectional data may not be the most
important SNPs in terms of change in trait, especially when
improvements are seen in the trait that underlies the
association.
A meta-analysis conducted by MAGIC (Meta-Analysis
of Glucose- and Insulin-related traits Consortium) identi-
fied SNPs associated with increased glycaemia and insulin
resistance in non-diabetic participants, using surrogate
measures of beta-cell function (HOMA-B) and insulin
sensitivity (HOMA-IR) in [35,000 participants (Dupuis
et al. 2009). MAGIC identified more than twelve robust
associations with fasting plasma glucose and beta-cell
function, but only two with HOMA-IR or fasting insulin as
a measure of insulin sensitivity. However, the studies
included in this meta-analysis used proxy measures of
insulin sensitivity and secretion, whilst in the current study,
we used detailed phenotyping from the IVGTT to fully
characterise insulin secretion and sensitivity by genetic
predisposition to T2D, albeit in a small number of partic-
ipants. Furthermore, examining these parameters before
and in response to a dietary intervention showed that the
effect of this genetic predisposition did not change the
ability to respond to environmental changes. Only a small
number of studies have examined the cumulative effect of
loci most strongly associated with risk of T2D in response
to an intervention or over time. The effects of a combined
GPS in the DPP are discussed above (Hivert et al. 2011).
An increased T2D risk score, composed of four alleles, has
been associated with an accelerated age-related decline in
beta-cell function in a longitudinal study (Haupt et al.
2009). In this case, a combined GPS from SNPs associated
with 2 h post-load glucose was shown to contribute to a
steeper age-related decline in glucose tolerance (Jensen
et al. 2011).
Despite the small sample size and potential insufficient
statistical power to examine effects of individual SNPs, in
an exploratory analysis, we found significant associations
of the TCF7L2 SNP with lower acute insulin secretion and
DI, but no association between this SNP and the change in
insulin secretion or DI in response to the intervention. The
sensitivity analysis, in which we excluded the TCF7L2
SNP from the GPS, indicated that the accumulation of risk
alleles, other than TCF7L2, still contributed to the
impairment of beta-cell function, although the effect was
not as strong. In participants from the DPP (n = 3548), the
T2D risk-conferring allele of TCF7L2, which was associ-
ated with proxy measures of insulin secretion, but not
sensitivity at baseline, also found no association with
change in these measures in response to metformin or
lifestyle interventions (Florez et al. 2006).
In conclusion, using detailed phenotyping from IVGTT,
we demonstrated that genetic predisposition to T2D is
associated with impaired beta-cell function in non-diabetic,
overweight participants on a high saturated fat diet, which
reflects an average ‘Western diet’. This genetic predispo-
sition did not moderate effects of a reduction in dietary
saturated fat by replacement with MUFA or carbohydrates
on changes in insulin sensitivity or beta-cell function.
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